Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer
NCT05410015 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2022-06-08
Summary
The relationship between immune inflammation-related protein complexes inblood and recurrence or metastasis of ovarian cancer will be studied
Conditions
Interventions
- OTHER
-
Normal clinical treatment without intervention
Normal clinical treatment without intervention
Sponsors & Collaborators
-
Peking Union Medical College Hospital
lead OTHER
Eligibility
- Min Age
- 20 Years
- Max Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-02-03
- Primary Completion
- 2024-02-03
- Completion
- 2026-02-03
Countries
- China
Study Locations
More Related Trials
-
Survival Outcomes of Ovarian Malignancies in Chinese Population
NCT03291262 ·Status: UNKNOWN
-
Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer
NCT06019923 ·Status: RECRUITING
-
Prognostic and Predictive Biomarkers in Ovarian Cancers
NCT03010124 ·Status: RECRUITING ·Phase: NA
-
Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab
NCT04770376 ·Status: UNKNOWN
-
The Efficacy of Hyperthermic Intraperitoneal Chemotherapy to Ovarian Cancer Patients With Homologous Recombination Repair Defect and Residual: a Prospective Cohort Study
NCT05265117 ·Status: UNKNOWN
-
Study on the Consistency Evaluation of Organoids Used in the Clinical Treatment of Ovarian Cancer With Anti-tumor Drugs
NCT05175326 ·Status: UNKNOWN
-
[68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer
NCT05903807 ·Status: RECRUITING ·Phase: PHASE2
-
Lymphadenectomy in Early Ovarian Cancer
NCT04710797 ·Status: RECRUITING ·Phase: NA
-
Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer
NCT03922776 ·Status: TERMINATED ·Phase: NA
-
Study Looking at Biomarkers in Ovarian Cancer
NCT03419689 ·Status: RECRUITING ·Phase: NA
-
Risk of Ovarian Cancer in Patients With a Pelvic Mass
NCT00315692 ·Status: COMPLETED
-
Prospective Cohort Study for Validation of Predictive Immune Biomarkers of Response to PAPR Inhibitors
NCT05640024 ·Status: RECRUITING
-
Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer
NCT06775470 ·Status: RECRUITING
-
The Culture of Advanced or Recurrent Ovarian Cancer Organoids and Drug Screening
NCT05290961 ·Status: UNKNOWN
-
Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer
NCT06907771 ·Status: RECRUITING
-
PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer
NCT04815408 ·Status: UNKNOWN ·Phase: PHASE2
-
Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers
NCT00086567 ·Status: COMPLETED
-
Development for the Peritoneal Carcinomatosis Index (PCI) in Ovarian Cancer
NCT01538498 ·Status: COMPLETED
-
Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
NCT01611766 ·Status: UNKNOWN ·Phase: PHASE3
-
Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve
NCT00712452 ·Status: TERMINATED ·Phase: NA
-
Ovarian Cancer Radiomics Approach in CT Led Evaluation
NCT06817174 ·Status: RECRUITING
-
New Biomarkers Evaluating Ovarian Cancer
NCT01466049 ·Status: COMPLETED
-
Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer
NCT03180177 ·Status: UNKNOWN ·Phase: PHASE3
-
Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases
NCT01048814 ·Status: COMPLETED
-
Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer
NCT05633199 ·Status: NOT_YET_RECRUITING ·Phase: NA